(VIANEWS) – PGS (PGS.OL), NEOEN (NEOEN.PA), SARTORIUS STED BIO (DIM.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. PGS (PGS.OL)
51.4% sales growth and 8.65% return on equity
PGS ASA, together with its subsidiaries, operates as a marine geophysical company in Norway and internationally. The company provides a range of seismic and reservoir services, including data acquisition, imaging, interpretation, and field evaluation to oil and gas companies, as well as carbon storage and offshore wind markets. The company was formerly known as Petroleum Geo-Services ASA and changed its name to PGS ASA in May 2019. PGS ASA was founded in 1991 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, PGS has a trailing twelve months EPS of kr0.42.
PE Ratio
PGS has a trailing twelve months price to earnings ratio of 21.48. Meaning, the purchaser of the share is investing kr21.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.65%.
More news about PGS.
2. NEOEN (NEOEN.PA)
48.5% sales growth and 6.44% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €0.94.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 27.91. Meaning, the purchaser of the share is investing €27.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
Volume
Today’s last reported volume for NEOEN is 300989 which is 88.61% above its average volume of 159578.
Sales Growth
NEOEN’s sales growth is 63.4% for the present quarter and 48.5% for the next.
More news about NEOEN.
3. SARTORIUS STED BIO (DIM.PA)
12.2% sales growth and 8.15% return on equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
More news about SARTORIUS STED BIO.
4. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through seven segments: Fishmeal, Fish Oil and Fish Feed; Freshwater FO; Freshwater SCT; Farming FO; Farming SCT; Services; and Sales & Other. The company's products include fresh and frozen whole salmon, fresh and frozen salmon fillets, fresh skin-packed salmon portions, frozen salmon portions and tails, frozen smoked salmon and salmon fillets, frozen salmon bits and pieces, frozen salmon off-cuts and belly flaps, frozen salmon heads, salmon backbones, and salmon skin under the Bakkafrost, 18 ISLANDS, HEIMLAND, BAKKA SALMON, NATIVE HEBRIDEAN, and LOCHLANDER brands. It is also involved in the production and sale of fishmeal, fish oil, and fish feed; production of eggs from breeding self-owned salmon strains; production of smolts; and on-growing of salmon. In addition, the company manages a fleet of farming service vessels; provides fish transportation, treatments, net cleaning, harvesting, freight ans logistical, and heavy marine support services; converts organic waste into biogas, heating, electricity, and fertilizers; produces styrofoam boxes; and optimizes the value creation and retention from the harvested fish. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr24.05.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 22.41. Meaning, the purchaser of the share is investing kr22.41 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BAKKAFROST’s EBITDA is 58.46.
Sales Growth
BAKKAFROST’s sales growth is 7.1% for the present quarter and 11.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 7.54B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 2, 2023, the estimated forward annual dividend rate is 15.63 and the estimated forward annual dividend yield is 2.69%.
More news about BAKKAFROST.
5. ZALARIS (ZAL.OL)
11.7% sales growth and 17.45% return on equity
Zalaris ASA provides full-service outsourced personnel and payroll services. It operates in two segments, Managed Services and Professional Services. The company offers a range of payroll and human resource (HR) outsourcing services, including payroll processing, time and attendance, and travel expenses, as well as cloud-based HR functionality services comprising talent management, digital personnel archive, HR analytics, mobile solutions, etc. It also engages in the implementation of SAP HCM, and Payroll and SuccessFactors; and provides consulting services. The company serves bank, insurance and financial services, health and life science, infrastructure and transportation, IT, technology and telecom, offshore and energy, products and industrials, retail, and service industries, as well as public services and other institutions. It operates in Norway, Sweden, Denmark, Germany, Finland, the United Kingdom, Latvia, Poland, Australia, and internationally. The company was formerly known as Zalaris HR Services AS and changed its name to Zalaris ASA in May 2014. Zalaris ASA was incorporated in 2000 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ZALARIS has a trailing twelve months EPS of kr1.53.
PE Ratio
ZALARIS has a trailing twelve months price to earnings ratio of 50.98. Meaning, the purchaser of the share is investing kr50.98 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.45%.
Yearly Top and Bottom Value
ZALARIS’s stock is valued at kr78.00 at 12:20 EST, way below its 52-week low of kr36.00.
Volume
Today’s last reported volume for ZALARIS is 4324 which is 63.59% below its average volume of 11876.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.1%, now sitting on 1.19B for the twelve trailing months.
Moving Average
ZALARIS’s worth is way higher than its 50-day moving average of kr70.77 and way above its 200-day moving average of kr51.73.
More news about ZALARIS.
